Clinical trials: Liver Biomarkers
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Hepatocellular Carcinoma, Contrast-enhanced Ultrasound
Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning
Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions
- Conditions
- Hepatocellular Carcinoma, Contrast-enhanced Ultrasound, Prognosis, Surgery
- Trial name
- NCT05257694
- Testing
- Surgery, Ablation (Microwave ablation or Radiofrequency ablation)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Ping Liang
Liver Transplantation
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
Most patients who get a liver transplant must take immunosuppressants for the rest of their lives. However, this has occurred at the expense of chronic CNI toxicity, e.g.
- Trial name
- NCT02736227
- Testing
- Tacrolimus Withdrawal and Everolimus Monotherapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.
Obese
Changes in Intrahepatic Lipids With Exercise
Individuals with obesity and particular type 2 diabetes have abnormally high levels of fat in liver cells and are at increased risk for cardiovascular and liver-related mortality.
- Trial name
- NCT02181270
- Testing
- high intensity exercise, continuous moderate exercise
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
HCC - Hepatocellular Carcinoma
A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predicting Conversion Therapy Response in Unresectable Hepatocellular Carcinoma
This study aims to identify early predictors for successful liver cancer treatment conversion. We will track changes in immune cells (CD8+ T-cells) in the blood during chemotherapy infusion (HAIC/TACE) combined with…
- Trial name
- NCT07117279
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Alcoholic Liver Diseases, Decompensated Cirrhosis
Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease
Fibroscan is a non invasive imaging investigation which measures liver stiffness, known to correlate well with liver scarring and cirrhosis on liver biopsy.
- Trial name
- BANDED (NCT01701687)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Nottingham
Acute Kidney Injury, Liver Cirrhoses
Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis
Acute kidney injury (AKI) is a common and under-diagnosed problem in patients with liver cirrhosis, and is associated with significant illness and preventable death.
- Conditions
- Acute Kidney Injury, Liver Cirrhoses, Biomarkers
- Trial name
- NCT03156426
- Testing
- Event of interest: Acute kidney injury
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- University of Edinburgh
Liver Cancer, Hepatocellular Carcinoma
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including…
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Cholangiocarcinoma
- Trial name
- HepQuant (NCT06899152)
- Testing
- HepQuant DuO, Multiparametric MRI Scans
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Montefiore Medical Center
Obese Adolescents, Overweight
Effect of Acute Exercise on Biochemical Parameters in Normal-Weight and Overweight/Obese Adolescent.
The goal of this interventional clinical trial is to compare the acute physiological and biochemical responses to maximal physical exercise (Spartacus test).
- Trial name
- NCT07103889
- Testing
- Spartacus Test
- Where
- Tunisia
- Volunteers
- 35 people
- Sponsor
- High Institute of Sports and Physical Education of Kef
Chronic Liver Disease
Effect of BCAA Supplementation on Muscle Mass, Muscle Quality and Molecular Markers of Muscle Regeneration in CLD Patients
Loss of muscle mass (sarcopenia) is a major complication in a patient with cirrhosis, impacting the disease outcome, quality of life and survival.
- Trial name
- BCAA-CLD (NCT04246918)
- Testing
- Branched Chain Amino Acid, Whey Protein concentrate powder
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Neoplasms
Hepatocellular Cancer (HCC) Screening in Zhongshan City
All participants in the selected communities will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be…
- Trial name
- HCC (NCT02501980)
- Testing
- Biomarker testing and Ultrasonography
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Liver Transplant Recipients, Liver Transplantation
Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients
The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant.
- Trial name
- PROGENI-LI (NCT01672164)
- Where
- 6 sites in United States
- Volunteers
- 202 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
NAFLD, Obesity
Biomarkers in the Diagnosis and Prognosis of NAFLD
Fibrosis is considered the leading cause of liver diseases and related mortality. Specifically, hepatic fibrosis is regarded as the consequence of reparative mechanisms initiated by hepatocytes in response to chronic damage.
- Conditions
- NAFLD, Obesity, Liver Fibrosis, Diabetes Mellitus, Type 2
- Trial name
- NCT06098417
- Testing
- Plasma Test, Liver biopsy, Visceral adipose tissue biopsy
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Trieste
Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease
Identification of Liver Fibrosis Biomarkers
Chronic liver disease (CLD) is a major cause of global mortality and morbidity . CLD patients are at an increased risk of developing liver fibrosis (formation of scar tissue), cirrhosis and liver failure and are at significant…
- Conditions
- Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
- Trial name
- NCT06819917
- Testing
- Identification of liver fibrosis biomarkers
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 575 people
- Sponsor
- Roche Diagnostics GmbH
Hepatocellular Carcinoma
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
A study to evaluate the efficacy and safety of icaritin versus huachansu in the first-line treatment of unresectable hepatocellular carcinoma with poor conditions and biomarker enrichment.
- Trial name
- BESTPOP (NCT05594927)
- Testing
- Icaritin, Huachansu
- Where
- 3 sites in China
- Volunteers
- 261 people
- Sponsor
- Beijing Shenogen Biomedical Co., Ltd
Colorectal Cancer
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01
- Trial name
- NCT02718430
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Vaximm GmbH
Fatty Liver Disease
Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in our environment. Preliminary data suggest that portal hypertension may exist in the initial phases of NAFLD due to mechanisms that…
- Trial name
- THESIS (NCT04191044)
- Testing
- A complete cardiovascular and liver characterization will be carried out
- Volunteers
- 170 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
Hypertension, Portal
Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)
This is a prospective, multi-center diagnostic trial conducted at 6 liver centers in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hepatic…
- Trial name
- NCT03713606
- Testing
- HVPG measurement
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- Nanfang Hospital, Southern Medical University